What is etoposide-platinum (EP) chemotherapy?
Etoposide-platinum chemotherapy, usually shortened to EP, is a combination of two chemotherapy drugs: etoposide and a platinum drug, either cisplatin or carboplatin. When carboplatin is used, the combination is sometimes written as EC or carboplatin-etoposide.
EP is one of the most important chemotherapy combinations in cancer care. It is the backbone of treatment for small cell lung cancer, one of the main options for testicular germ cell tumours, and a standard choice for many neuroendocrine carcinomas that behave like small cell lung cancer in other organs.
The two drugs attack cancer cells in different ways, so together they work better than either drug alone. EP is given into a vein in cycles, with rest periods in between so the body can recover.
The drugs in EP
| Drug | Type | How it is given |
|---|---|---|
| Etoposide | Topoisomerase II inhibitor, derived from the May apple plant | Into a vein over about an hour, usually on 3 consecutive days; sometimes as capsules |
| Cisplatin | Platinum drug | Into a vein with extra fluids before and after, usually on day 1 or split over several days |
| Carboplatin | Platinum drug, gentler on the kidneys and nerves | Into a vein over 30-60 minutes on day 1 |
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Combination chemotherapy |
| Main uses | Small cell lung cancer, testicular cancer, neuroendocrine carcinomas |
| How it is given | Drip into a vein, as an outpatient or short hospital stay |
| Cycle length | Usually every 21 days |
| Number of cycles | Usually 4-6 for small cell lung cancer; 4 for testicular cancer |
| Total course | About 3-4 months |
| Common side effects | Low blood counts, tiredness, nausea, hair loss, numbness, hearing changes |
| Often combined with | Radiotherapy or immunotherapy, depending on the cancer |
A brief history
Cisplatin was found to have anticancer activity in the 1960s, after researchers noticed that platinum compounds stopped bacteria from dividing. Etoposide was developed from a natural substance in the May apple plant. Combining the two in the 1970s and 1980s transformed the outlook for testicular cancer and became the standard approach for small cell lung cancer.
2. How it works
Cancer cells divide more often than most normal cells. Both drugs in EP damage the DNA that a cell needs to copy before it divides.
| Drug | Mechanism |
|---|---|
| Etoposide | Blocks an enzyme called topoisomerase II, which normally cuts and rejoins DNA strands as they unwind. Etoposide traps the enzyme mid-way, leaving breaks in the DNA. |
| Cisplatin or carboplatin | Forms cross-links between DNA strands so they cannot separate to be copied. |
When the DNA damage is too great to repair, the cell triggers its own death. Normal cells that divide quickly, such as those in the bone marrow, hair roots and gut lining, are also affected, which explains most side effects.
3. Who it is for
Conditions treated
| Condition | Role of EP |
|---|---|
| Small cell lung cancer | Standard first treatment; given with chest radiotherapy for limited stage and with immunotherapy for extensive stage |
| Testicular germ cell tumours | Four cycles of EP are an option for good-prognosis spread disease; bleomycin is added in the BEP regimen |
| Primary mediastinal germ cell tumour | Used within platinum-based combinations |
| Ovarian germ cell tumours | Given as BEP after surgery in many cases |
| Large cell neuroendocrine carcinoma of the lung | Often treated with small cell-type chemotherapy |
| Small cell neuroendocrine carcinoma of the cervix | Combined with radiotherapy or surgery |
| Small cell neuroendocrine carcinoma of the bladder | Given before surgery or with radiotherapy |
| Intracranial germ cell tumours | Platinum and etoposide are used with radiotherapy |
Cisplatin or carboplatin?
| Situation | Usual choice |
|---|---|
| Aiming for cure in testicular cancer | Cisplatin, as it is more effective in this cancer |
| Limited-stage small cell lung cancer with radiotherapy | Cisplatin often preferred; carboplatin if cisplatin is unsuitable |
| Extensive-stage small cell lung cancer | Carboplatin is commonly used, especially with immunotherapy |
| Kidney problems, hearing loss or nerve damage | Carboplatin |
| Frailty or heart problems | Carboplatin, as it needs less fluid |
Why EP is combined with other treatments
Radiotherapy. In limited-stage small cell lung cancer, giving chest radiotherapy at the same time as EP, starting early in the course, controls the cancer in the chest better than chemotherapy alone. Radiotherapy to the brain may also be offered later to lower the risk of spread there.
Immunotherapy. In extensive-stage small cell lung cancer, a checkpoint inhibitor such as atezolizumab or durvalumab is now commonly added to platinum and etoposide and then continued on its own as maintenance. This approach helps some people live longer than with chemotherapy alone.
4. Before treatment
| Step | Why it is done |
|---|---|
| Blood tests | Check blood counts, kidney and liver function |
| Kidney function test | Guides the platinum dose |
| Hearing test | Recommended before cisplatin |
| Weight and height | Used to calculate doses |
| Fertility discussion | Sperm or egg storage before treatment if wanted |
| Dental check | Sometimes advised to reduce infection risk |
| Venous access | A cannula, or a PICC or port line if veins are difficult |
5. What to expect: step by step
A typical 21-day cycle
| Day | What happens |
|---|---|
| Day 1 | Blood tests; anti-sickness medicines; fluids; platinum drug; etoposide |
| Days 2-3 | Etoposide again, as a drip or capsules |
| Days 4-7 | Nausea and tiredness are often worst |
| Days 7-14 | Blood counts are lowest; infection risk is highest |
| Days 15-21 | Recovery; blood counts rise again |
| Day 22 | Next cycle starts if blood tests are satisfactory |
On a treatment day
| Step | What happens |
|---|---|
| 1. Check-in | You are weighed and your blood results are checked |
| 2. Cannula or line | A drip is connected |
| 3. Anti-sickness medicines | Given as tablets or into the vein |
| 4. Hydration | With cisplatin, several hours of fluids help protect the kidneys |
| 5. Chemotherapy | The drugs are given one after another |
| 6. Monitoring | Nurses watch for reactions and measure urine output with cisplatin |
| 7. Going home | You go home with anti-sickness tablets and contact numbers |
6. Side effects and risks
| Side effect | How common | What helps |
|---|---|---|
| Low white cells and infection risk | Very common | Check temperature; call your team urgently for fever |
| Anaemia and tiredness | Very common | Rest; transfusion if needed |
| Low platelets and bruising | Common | Report unusual bleeding |
| Nausea and vomiting | Common, especially with cisplatin | Anti-sickness medicines taken regularly |
| Hair loss | Common | Usually grows back after treatment |
| Sore mouth | Common | Mouthwashes and soft toothbrush |
| Numbness or tingling in hands and feet | Common with cisplatin | Tell your team early; dose may be adjusted |
| Hearing loss or ringing in the ears | Common with cisplatin | Hearing tests; may be permanent |
| Kidney problems | Possible with cisplatin | Fluids and blood tests |
| Low magnesium and potassium | Common with cisplatin | Supplements |
| Reduced fertility | Possible | Sperm or egg storage beforehand |
| Second blood cancer | Rare, years later | Linked to etoposide at high cumulative doses |
Neutropenic sepsis
A temperature of 38 C or higher, or feeling suddenly unwell, during chemotherapy can be a sign of serious infection when white cell counts are low. This is an emergency. Call your chemotherapy helpline straight away, even at night.
7. Results and outlook
| Study | Main finding |
|---|---|
| Intergroup 0096, limited small cell lung cancer (417 people) | Four cycles of cisplatin and etoposide with chest radiotherapy started in the first cycle; twice-daily radiotherapy gave a five-year survival of 26% versus 16% with once-daily treatment, but more severe oesophagitis (Turrisi et al., 1999) |
| IMpower133, extensive small cell lung cancer (403 people) | Adding atezolizumab to carboplatin and etoposide increased median survival from 10.3 to 12.3 months (Horn et al., 2018) |
| Indiana University BEP follow-up (118 men) | Three and four cycles of BEP gave similar long-term survival in good-prognosis germ cell tumours (Saxman et al., 1998) |
| Review of advanced germ cell tumours | Three cycles of BEP or four cycles of EP are recommended for good-prognosis disease (Haugnes et al., 2014) |
Small cell lung cancer usually responds quickly to EP, and many people feel better within weeks. Unfortunately, it often returns. Testicular germ cell tumours, by contrast, are frequently cured with platinum-based chemotherapy, even when they have spread.
8. Recovery and aftercare
During treatment
- Take anti-sickness medicines as prescribed, even if you feel well
- Drink plenty of fluids, especially in the days after cisplatin
- Avoid crowds and people with infections when counts are low
- Eat small, frequent meals if your appetite is poor
- Stay gently active to reduce tiredness
After treatment
| Period | What to expect |
|---|---|
| 2-4 weeks after the last cycle | Tiredness starts to lift; blood counts recover |
| About 1-3 months | Scans to check response; hair starts to regrow |
| Months to years | Numbness and hearing changes may improve slowly or persist |
| Long term | Follow-up appointments and scans |
Late effects in testicular cancer survivors
Because many men are cured young, late effects matter. A review highlighted second cancers and heart and blood vessel disease as the most serious long-term effects, and recommended a healthy lifestyle for survivors (Haugnes et al., 2014).
| Late effect | What can help |
|---|---|
| Heart disease and high blood pressure | Regular checks of blood pressure, cholesterol and weight |
| Second cancers | Routine screening and reporting new symptoms |
| Hearing loss and tinnitus | Hearing aids if needed |
| Nerve damage | Physiotherapy and pain management |
| Low testosterone | Blood tests and replacement if needed |
Coping with chemotherapy
Chemotherapy can affect your mood as well as your body. Many people feel anxious before each cycle or low during the days when tiredness is worst. Keeping a simple diary of symptoms helps you and your team spot patterns and adjust medicines. Support from family, friends, specialist nurses and patient groups can make a real difference.
Eating well
Nausea, taste changes and a sore mouth can make eating hard. Try bland, cool foods, small snacks through the day and nourishing drinks. If you are losing weight, ask to see a dietitian.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Carboplatin-etoposide | When cisplatin is unsuitable |
| Irinotecan with platinum | Used in some countries for small cell lung cancer |
| BEP | Testicular and ovarian germ cell tumours |
| VIP (etoposide, ifosfamide, cisplatin) | Germ cell tumours when bleomycin must be avoided |
| Surveillance or surgery | Early-stage testicular cancer |
| Immunotherapy added to chemotherapy | Extensive-stage small cell lung cancer |
| Radiotherapy alone | Some cancers or when chemotherapy is not possible |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Will I lose my hair? | Usually yes, but it regrows after treatment |
| Can I work during treatment? | Some people work part time; it depends on how you feel |
| Do I need to stay in hospital? | Usually not, though cisplatin can mean a long day or a short stay |
| Is etoposide available as tablets? | Yes; capsules are sometimes used on days 2 and 3 |
| Can I drink alcohol? | Small amounts are usually fine, but check with your team |
| Will I be able to have children? | Many people can, but storing sperm or eggs beforehand is advised |
| How will I know it is working? | Scans after two or three cycles, and blood markers for some cancers |
11. Questions to ask your care team
- Will I have cisplatin or carboplatin, and why?
- How many cycles will I need?
- Will I also have radiotherapy or immunotherapy?
- What should I do if I get a fever?
- Should I have a hearing test first?
- What support is available for nausea and tiredness?
- What late effects should I watch for after treatment?
Resources
- Haugnes, H.S., Stephenson, A.J. and Feldman, D.R. (2014) ‘Beyond stage I germ cell tumors: current status regarding treatment and long-term toxicities’, American Society of Clinical Oncology Educational Book, 34, pp. e180-e190.
- Horn, L. et al. (2018) ‘First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer’, New England Journal of Medicine, 379(23), pp. 2220-2229.
- Saxman, S.B. et al. (1998) ‘Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience’, Journal of Clinical Oncology, 16(2), pp. 702-706.
- Turrisi, A.T. et al. (1999) ‘Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide’, New England Journal of Medicine, 340(4), pp. 265-271.
- National Cancer Institute (2026) Small Cell Lung Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.